Navigation Links
A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List

In an otherwise bleak healthcare scenario has emerged a heartening development.The World Health Organisation (WHO) has designated Paromomycin IM injection manufactured by the US based Institute for OneWorld Health, a non-profit drug firm, for inclusion in its Model List for Essential Medicines.

Paromomycin IM Injection is a cost-effective treatment for visceral leishmaniasis (VL), the worlds second most deadly parasitic disease after malaria.

It is a systemic infection caused by various species of Leishmania parasites. The infection is transmitted by sandflies and causes chronic fever, weight loss, anemia and spleen and liver and anemia. With approximately 500,000 new cases occurring annually worldwide, visceral leishmaniasis, also known as kala azar, primarily afflicts the rural poor.

Left untreated, VL is nearly always fatal. VL currently occurs in 62 countries, primarily in the developing world. Of the approximately 500,000 new cases of VL occurring annually, 90% are found in just five countries: India, Bangladesh, Nepal, Sudan and Brazil.

The Indian subcontinent carries 70% of all estimated new VL cases per year worldwide, with India alone is burdened with 50% percent of all new cases. The most affected state in India is Bihar, but VL is also endemic in the states of Jharkand, West Bengal, and Uttar Pradesh.

Paromomycin, an off-patent aminoglycoside antibiotic, is an established drug with an extensive and well-characterized safety profile. Paromomycin IM Injection is now available for the first time as a new treatment of VL as a once-a-day injection for 21 days. The cost of Paromomycin IM Injection is significantly lower than other currently approved VL therapies.

The WHO List of Essential Medicines provides a model for countries to select medicines addressing public health priorities. Medicines are selected by the WHOs Expert Committee on the Selection and Use of Essential Med icines based on its quality, safety and efficacy standards. The WHO List of Essential Medicines helps governments address problems of cost and availability and provides guidance to the pharmaceutical industry on medicine needs globally.

The decision was made at the 15th Expert Committee on the Selection and Use of Essential Medicines, which met in Geneva earlier this year. In its letter notifying OneWorld Health of its decision, the WHO noted that, Paromomycin appears to be the most cost-effective treatment among all available alternatives.

The inclusion of OneWorld Healths first approved drug product on the WHO Essential Medicines List recognizes the value of Paromomycin IM Injection to combat this lethal disease. This recognition is an important step in the realization of our drug development mission: Bringing the promise of safe, effective, and affordable medicines to those most in need, said Dr. Ahvie Herskowitz, OneWorld Healths Co-founder and Chief Medical Officer.

Gland Pharma Limited, the Hyderabad, India-based drug manufacturer working with OneWorld Health and its collaborators, received regulatory approval from the Drug-Controller General - India (DCGI) for Paromomycin IM Injection as a treatment for VL on August 31, 2006. Gland has committed to act as the low cost global manufacturer to ensure access of Paromomycin to all those that need it.

WHO first published the first Model List of Essential Drugs in 1977, identifying 208 individual medicines that together could provide safe, effective treatment for the majority of communicable and non-communicable diseases. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford.

Many international organizations, including UNICEF and the U.N. High Commission for Refugees (UNHCR), as well as other nongovernmental organizations and international non-profit supply agencies, have adopted the essential medicines concept and base their medicine supply system on WHOs list.


Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
10. Injection supports Heart Devices
11. Abstinence From Alcohol With The Help Of An Injection
Post Your Comments:

(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: